mpathic + MADRS-ECOA

At mpathic, we’re exploring how AI can enhance the quality and consistency of clinician-administered outcome assessments (COAs) in psychedelic clinical trials. This poster highlights findings from a real-world study showing that our AI model reliably detects scoring and administration issues on depression scales like the MADRS. The results demonstrate the potential of AI to improve rater performance, reduce variability, and support data integrity in clinical research.